GLP-1 Side Effects: What to Actually Expect

Most GLP-1 side effects are gastrointestinal, dose-dependent, and improve with time. A small number are serious and require immediate attention. Here is what the data show and how to manage common issues.

Last updated May 1, 2026.

Most Common Side Effects

• Nausea — 15–45% of patients in trials, peaks during dose escalation
• Diarrhea — 8–15%
• Constipation — 11–24%
• Vomiting — 5–24%, more common early
• Abdominal pain or discomfort
• Reduced appetite (often desired, but uncomfortable for some)
• Fatigue, headache in first weeks
• Injection site reactions (mild)

Most resolve within 4–8 weeks as the body adapts.

Managing GI Symptoms

• Slow titration. Stay on a tolerated dose longer if needed before escalating.
• Smaller meals, slower eating. The drug slows gastric emptying; large fast meals trigger nausea.
• Low-fat meals. High-fat meals worsen nausea on GLP-1.
• Hydration. Maintain fluid intake even when appetite is reduced.
• Anti-nausea medication. Your provider can prescribe ondansetron or other short-term agents if needed.
• Fiber and stool softeners for constipation. Magnesium oxide or polyethylene glycol can help.

Less Common but Serious Side Effects

Pancreatitis

Severe persistent abdominal pain that often radiates to the back, with or without vomiting, may indicate acute pancreatitis. The absolute risk is low but real. Stop the medication and seek medical care urgently if these symptoms occur. People with prior pancreatitis history should not take GLP-1s.

Gallbladder Events

Rapid weight loss from any cause increases gallstone risk. GLP-1 trials have shown a small but real increase in gallbladder events. Symptoms: severe right upper quadrant pain, fever, jaundice. Contact your provider for evaluation.

Severe Hypoglycemia

GLP-1 alone has low hypoglycemia risk because insulin release is glucose-dependent. When combined with insulin or sulfonylureas, hypoglycemia risk rises significantly. Dose adjustments are often needed when starting GLP-1 alongside other diabetes drugs.

Allergic Reactions

Anaphylaxis and angioedema have been reported, though rarely. Stop medication and seek emergency care for hives, swelling, difficulty breathing.

Acute Kidney Injury

Often a consequence of dehydration from severe vomiting/diarrhea, not the drug directly. Adequate fluid intake during dose escalation reduces risk.

Diabetic Retinopathy (in T2D)

Rapid improvement in HbA1c can transiently worsen diabetic retinopathy in patients with pre-existing disease. Eye exam screening before starting is recommended for patients with diabetic eye disease.

FDA Boxed Warning: Thyroid C-Cell Tumors

All GLP-1 receptor agonists carry an FDA boxed warning because they caused medullary thyroid C-cell tumors in rodents. A causal link in humans has not been established despite extensive surveillance. People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN-2) should not take GLP-1s.

Long-Term Safety: What 5+ Years of Data Show

Cardiovascular outcomes trials have been broadly reassuring or beneficial:

• SUSTAIN-6 (semaglutide in T2D): reduced MACE
• LEADER (liraglutide in T2D): reduced MACE
• REWIND (dulaglutide in T2D): reduced MACE
• SELECT (semaglutide in CVD without diabetes): reduced MACE
• SURPASS-CVOT (tirzepatide vs dulaglutide CV outcomes): ongoing

Areas under continued study: bone mineral density, mental health (case reports of suicidal ideation are under FDA review with no causal signal yet established), long-term GI motility, and rare adverse events.

"Ozempic Face" and Cosmetic Concerns

Rapid weight loss can cause facial volume loss — sunken cheeks, deeper folds — sometimes called "Ozempic face." It is not unique to GLP-1; any rapid weight loss does this. Slower titration to a sustainable rate of weight loss minimizes the visible change.

Muscle Loss

Like any rapid weight loss, 20–40% of weight lost on GLP-1 may be lean tissue. Adequate protein intake (1.2–1.6 g/kg) and resistance training significantly reduce muscle loss.

Mental Health Considerations

Most patients report stable or improved mood with successful weight loss. The FDA has reviewed case reports of suicidal ideation in patients on GLP-1s and has not established a causal link as of the latest review. Patients with depression or eating disorder history should discuss with their provider.

When to Call Your Doctor

• Severe persistent abdominal pain (pancreatitis)
• Persistent vomiting or inability to keep fluids down (risk of dehydration, AKI)
• Yellowing of skin or eyes (gallbladder)
• Severe hypoglycemia (if on insulin or sulfonylureas)
• Difficulty swallowing or breathing, hives (allergic reaction)
• New or worsening vision changes (in diabetes)
• Thoughts of self-harm

For medical emergencies, call 911.

Who Should Not Take GLP-1

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia type 2 (MEN-2)
• History of pancreatitis
• Severe gastroparesis or other significant GI motility disorder
• Pregnancy or planning pregnancy (discontinue 2 months before)
• Known hypersensitivity to the drug
• Children below approved age (varies by drug)

Related Reading

• Is Ozempic Safe?
• Is Semaglutide Safe?
• GLP-1 Weight Loss
• How to Get GLP-1 Online

Sources

• FDA prescribing information for Ozempic, Wegovy, Mounjaro, Zepbound.
• SUSTAIN-6, LEADER, REWIND, SELECT cardiovascular outcomes trials.
• FDA Adverse Event Reporting System (FAERS) signal reviews.